U.S. House committee launches probe of Allergan patent deal

Go back to U.S. House committee launches probe of Allergan patent deal

Mylan (MYL) PT Raised to $36 at Cowen; Reiterates Market Perform

October 4, 2017 10:44 AM EDT

Cowen raised its price target on Mylan (NASDAQ: MYL) to $36.00 (from $30.00) while maintaining a Market Perform rating. Cowen updated its model to reflect a potential $800MM in generic Copaxone contribution in 2018, and then modestly declining with other competition.

With this approval the... More